Approximately 40 percent of melanomas lack sufficient infiltration of immune cells within the tumor and therefore have poor responses to immunotherapies
Until now, there was no way to identify patients with an increased risk of recurrence.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.